We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
77 ELEKTRONIKA

Download Mobile App




Events

31 Jul 2024 - 02 Aug 2024
02 Aug 2024 - 04 Aug 2024
20 Aug 2024 - 22 Aug 2024

Novel Technology Illuminates Lung and Ovarian Cancer during Surgery

By HospiMedica International staff writers
Posted on 18 Jan 2024
Print article
Image: CYTALUX is the only targeted imaging agent designed to “highlight” ovarian and lung cancer in the body (Photo courtesy of On Target)
Image: CYTALUX is the only targeted imaging agent designed to “highlight” ovarian and lung cancer in the body (Photo courtesy of On Target)

Preoperative scans and surgical skills are vital tools for a successful surgery. However, ovarian and lung cancer cells are not always visible to the naked eye and can hide in plain sight. Now, a novel technology that illuminates lung and ovarian cancer during surgery provides surgeons with an additional measure of “sight” to help them identify the cancer as they operate.

CYTALUX, a novel compound from On Target Laboratories (West Lafayette, IN, USA), is the only FDA-approved molecular imaging agent that illuminates lung and ovarian cancer as an adjunct during surgery, enabling surgeons to detect more cancer for resection. It is the only targeted imaging agent designed to “highlight” ovarian and lung cancer in the body, helping surgeons to see it in real-time, as they operate. This added measure of visibility in the operating room can help the surgeon find cancer that may have otherwise been missed. CYTALUX targets the folate receptors commonly found in many cancers, binds to the cancerous tissue, and illuminates under near-infrared light. A single dose of the agent is administered via intravenous infusion before surgery and assists surgeons in visually identifying additional cancerous tissue to be removed during the operation.

CYTALUX has been proven to help surgeons detect more cancer for removal. In clinical trials, CYTALUX detected additional ovarian and lung cancer that wouldn’t have been detected otherwise. In the ovarian cancer trial, additional lesions were found in 27% of patients that were not identified with conventional methods. In the lung cancer trial, the primary lung lesion was localized in 19% of patients, but not detected with conventional methods. Additionally, in 8% of patients, one or more synchronous malignant lesions not detected by pre-operative imaging were identified.

 

Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
1.5T Superconducting MRI System
uMR 680

Print article

Channels

Critical Care

view channel
Image: Peerbridge Cor is a 3-lead, 2-channel wireless AECG that simplifies the testing and diagnostic process (Photo courtesy of Peerbridge Health)

First-of-its-Kind Trial to Measure Ejection Fraction Severity Directly from AI-Enabled Remote ECG Wearable

Echocardiograms are a standard diagnostic tool to measure ejection fraction but require a clinical setting for administration. This can pose challenges such as scheduling delays, staffing shortages, accessibility... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: POCT offers cost-effective, accessible, and immediate diagnostic solutions (Photo courtesy of Flinders University)

POCT for Infectious Diseases Delivers Laboratory Equivalent Pathology Results

On-site pathology tests for infectious diseases in rural and remote locations can achieve the same level of reliability and accuracy as those conducted in hospital laboratories, a recent study suggests.... Read more

Business

view channel
Image: The Innovalve transseptal delivery system is designed to enable safe deployment of the Innovalve implant (Photo courtesy of Innovalve Bio)

Edwards Lifesciences Acquires Sheba Medical’s Innovalve Bio Medical

Edwards Lifesciences (Irvine, CA, USA), a leading company in medical innovations for structural heart disease and critical care, has acquired Innovalve Bio Medical LTD. (Ramat Gan, Israel), an early-stage... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.